Afrezza Inhaled Insulin for Pediatric Diabetes

Afrezza Inhaled Insulin for Pediatric Diabetes
80%69%58%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 21 • YES 62.0%May 22 • YES 62.0%May 24 • YES 76.2%May 27 • YES 66.4%
Mannkind Corporation ($MNKD)
No stock close$3.64$3.26$2.87May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 18 • MNKD $2.99May 19 • MNKD $2.96May 20 • MNKD $3.25May 21 • MNKD $3.31May 22 • MNKD $3.38May 26 • MNKD $3.53May 27 • MNKD $3.55

Will this trial show a positive result on change in HbA1c?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle
Primary Completion
10/3/24
Study Completion
4/29/25
Sponsor
Mannkind Corporation
Ticker
$MNKD
Type
Phase 3
Trial Status
Completed
Trial Size
319
NCT
NCT04974528
Trial Description
This study tests Afrezza inhaled insulin in children and teens with type 1 or type 2 diabetes, measuring HbA1c blood sugar control at 26 weeks.